Bioavailability of Vagantin® Coated Tablets Relative to an Oral Methantheline Bromide Solution

Inclusion Criteria:

• age: 18 - 45 years

• sex: male and female

• ethnic origin: Caucasian

• body weight: ±20 % of normal weight (Broca)

• good health as evidenced by the results of the clinical examination and the laboratorycheck-up which are judged by the clinical investigator not to differ in a clinicalrelevant way from the normal state

• written informed consent

Exclusion Criteria:

• known hypersensitivity to the investigational products or to their adjuvants

• pollakisurie of cardial and renal reasons

• megacolon

• atonia of the gastrointestinal tract

• atonia or hypotonia of the urinary bladder

• tachycardiac arrhythmia

• subvesical bladder obstruction, especially benign prostatic hypertrophy

• narrow angle glaucoma

• glasses or contact lenses

• history of gastrointestinal diseases (except appendectomy)

• history of renal and/or hepatic diseases

• any disease known to modify absorption, metabolism or excretion of the drug underinvestigation

• liability to orthostatic dysregulation, faintings, or blackouts

• alcohol consumption more than 40 g/day

• smokers of more than 10 cigarettes per day

• special or uniform nutritional habits, e.g. vegetarians or under-caloric diet

• less than 14 days after last acute disease

• less than 14 days after last systemic or local drug administration or 10 times thehalf life of the respective drug (except hormonal contraceptives)

• blood donation within the last two months

• blocking period due to another clinical study with investigational products; howeverat least 4 weeks after the end of the study or 10 times the half life of therespective drug

• lack of willingness or inability to co-operate adequately

• HIV and HBV and drug screening positive or not performed (in case of a positiveHIV-test, the volunteers must be informed by a physician in a personal conversation)

• lactation and pregnancy test positive or not performed